HAEMONETICS CORP — Director's Dealing 2010

Apr 1, 2010

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GLOBAL MED TECHNOLOGIES INC (GLOB)
CIK: 0001009463
Period of Report: 2010-03-25

Reporting Person: HAEMONETICS CORP (10% Owner)
Reporting Person: Atlas Acquisition Corp. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	31428730	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$0.72		Common Stock (5500000)		Indirect

Footnotes

F1: The reported securities are owned indirectly by Haemonetics Corporation ("Haemonetics") and directly by Atlas Acquisition Corp. ("Atlas"), a wholly-owned subsidiary of Haemonetics. The reported securities were acquired by Atlas in connection with the cash tender offer to purchase all outstanding shares of convertible preferred stock and Common Stock of the Issuer commenced by Atlas on February 19, 2010.

F2: Subject to the "blocker" provisions described in footnote 3, the convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

F3: The convertible preferred stock is subject to "blocker" provisions prohibiting the holder from converting the preferred stock to the extent that such conversion would result in the holder being deemed the beneficial owner of more than 9.99% of the issued and outstanding shares of the Common Stock.

F4: Subject to the "blocker" provisions described in footnote 3, the shares of convertible preferred stock are convertible at a rate of 1-to-1,388.89 into the number of shares of Common Stock shown in column 3.